International Journal of Current Science Research and Review ISSN: 2581-8341 Volume 06 Issue 06 June 2023 DOI: 10.47191/ijcsrr/V6-i6-16, Impact Factor: 6.789 IJCSRR @ 2023 www.ijcsrr.org 3223 * Corresponding Author: Ravi V. Patel Volume 06 Issue 06 June 2023 Available at: www.ijcsrr.org Page No. 3223-3239 Development and Characterization of Solid Dispersion of Rasagilline Mesylate for Improvement of Dissolution Rate Using Hydrophilic Carriers Ravi V. Patel 1 , Gazala Y. Ansari 2 , Jitendra O. Bhangale 3 1 Arihant School of Pharmacy & BRI 2,3 Smt. N. M. Padalia Pharmacy College, Sarkhej Changodar Road, Navapura, Ahmedabad-382210, Gujarat, India ABSTRACT: The aim of present study was to improve the solubility of Rasagilline mesylate, an Atypical Antipsychotic agent which is BCS Class III drug and thus has very low solubility and hence very poor bioavailability owing to less absorption. Moreover Rasagilline mesylate has a bitter taste. Thus in the present study an attempt was made to taste mask the bitter taste of drug and improve oral bioavailability of drug by formulating the drug into solid dispersion and then formulate the solid dispersions into Fast Dissolving Tablets. Solid Dispersions of Rasagilline mesylate were formulated using various polymers like Plasdone K30, plasdone K90, Eudragit RS100, Eudragit RL 100, Poloxamer 188 and Soluplus in different ratios viz., 1:1 and 1:2 by solvent evaporation method and evaluated for various physicochemical parameters. On the basis of evaluation parameters Solid Dispersion containing Drug : Soluplus :: 1 : 2 was optimized batch having Solubility 1.91 mg/ml, Drug content 102.75 % and % CDR of 98.43 % at 35 mins. For formulating Fast Dissolving Tablets, 3 2 factorial designs was applied where the batch SD12 and Concentration of Chitosan were taken as dependent variable X1 and X2, respectively and wetting time (sec.) and in vitro disintegration time (sec.) and % CDR were taken as an independent variables. All the formulation prepared by applying experimental design showed more than 93 % drug release in 15 mins. Batch F9 was selected as an optimized batch from the data of overlay plot, drug release kinetics and checkpoint batch. A stability study for optimized formulation was carried out as per ICH guidelines, showed no significant changes in the evaluation parameters. Thus from the study it can be concluded that Fast Dissolving Tablets of Rasagilline mesylate formulated from solid dispersions can provide rapid drug release within a short period of time. KEYWORDS: Rasagilline mesylate, Solid Dispersion, solvent evaporation method, Fast Dissolving Tablets, Effervescent method, Wetting time, In Vitro disintegration time, % CDR. INTRODUCTION The development of many active pharmaceutical ingredients (APIs) has been discontinued because of their low aqueous solubility, which leads to poor bioavailability. Some of these drugs belong to Biopharmaceutical Classification System (BCS) Class II compounds, which are characterized by low aqueous solubility and high permeability. The urgency to ‘enhanced solubility’ of BCS Class III APIs has generated special interest to the pharmaceutical scientists to achieve better oral bioavailability. Out of numerous formulation strategies. The oral route of administration still continues to be the most preferred route due to its manifold advantages including ease of ingestion, pain avoidance, versatility and most importantly patient compliance. The most popular solid dosage forms are tablet and capsule. One drawback of these dosage forms however is the difficulty to swallow. Dysphasia or difficulty in swallowing is seen nearly 35% in the general population. Many elderly persons will have difficulties in taking conventional solid dosage form (tablets and capsules) because of their hand tremors and dysphasia. Swallowing problems are also common in young individuals because of their under developed muscular system. In some cases such as motion sickness, sudden episode of allergic attack or coughing and an unavailability of water, swallowing of tablets may become difficult. To fulfill these medical needs, the pharmaceutical technologist have devoted considerable effort to develop a novel type of dosage form for oral administration, the Fast Dissolving Tablet (FDT), tablet that disintegrates and dissolves rapidly in saliva without need of water. The FDT usually dissolve in oral cavity within 15 to 60 s. The faster the drug goes into solution, the quicker the absorption and onset of clinical effects. The development of fast dissolving tablets also provides line extension in the market place. Advantages of rapid disintegrating drug delivery system over conventional dosage forms include fast drug absorption, quick drug therapy intervention, convenience of administration and patient acceptance,